Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections
FOSTER CITY, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced an additional award of $3.2 million from CARB-X to advance development of VAX-A1, a novel vaccine designed to prevent infections caused by Group A Streptococcus pyogenes (Strep) bacteria.